614 related articles for article (PubMed ID: 26572704)
1. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
2. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
3. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
5. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
6. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
9. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
10. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
11. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
12. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
[TBL] [Abstract][Full Text] [Related]
13. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
15. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
17. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
18. The Role of the AT-Rich Interaction Domain 1A Gene (
Li JJ; Lee CS
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
20. The emerging roles of ARID1A in tumor suppression.
Wu RC; Wang TL; Shih IeM
Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
